Experienced in Hyperaldosteronism

Dalong L. Zhu

No 321, Zhongshan Road, 
Nanjing, CN 
Experienced in Hyperaldosteronism
No 321, Zhongshan Road, 
Nanjing, CN 
OverviewLocationsClinical Research

Overview

Dalong Zhu practices in Nanjing, China. Zhu is rated as an Experienced expert by MediFind in the treatment of Hyperaldosteronism. Their top areas of expertise are Type 2 Diabetes (T2D), Diabetic Neuropathy, Cushing's syndrome, Gastric Bypass, and Bone Marrow Transplant.

Their clinical research consists of co-authoring 183 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 3 articles in the study of Hyperaldosteronism.

Locations

No 321, Zhongshan Road, Nanjing, 210008, China
Other Locations
321 Zhongshan Road, Nanjing, 210008, China
Zhongshan Road, Nanjing, 210008, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

An Investigator-initiated, Prospective, Randomized, Open Label, Parallel Study to Explore and Evaluate the Therapeutic Effects of Liraglutide, Empagliflozin and Linagliptin on the Cognitive Function, Olfactory Function, and Odor-induced Brain Activation in T2DM Patients With Mild Cognitive Impairment.
An Investigator-initiated, Prospective, Randomized, Open Label, Parallel Study to Explore and Evaluate the Therapeutic Effects of Liraglutide, Empagliflozin and Linagliptin on the Cognitive Function, Olfactory Function, and Odor-induced Brain Activation in T2DM Patients With Mild Cognitive Impairment.
Enrollment Status: Active_not_recruiting
Publish Date: June 27, 2025
Intervention Type: Drug
Study Phase: Not Applicable
A Phase Ib Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SY-008 After Multiple Ascending Doses in Patients With Type 2 Diabetes Mellitus
A Phase Ib Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SY-008 After Multiple Ascending Doses in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: May 18, 2022
Intervention Type: Drug
Study Drug: SY-008
Study Phase: Phase 1
A Phase Ib Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SY-009 After Multiple Ascending Doses in Patients With Type 2 Diabetes Mellitus
A Phase Ib Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SY-009 After Multiple Ascending Doses in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: April 01, 2022
Intervention Type: Drug
Study Drug: SY-009
Study Phase: Phase 1
A 24-week Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of HMS5552 With Additional 28-week Open-label Treatment to Evaluate the Safety of HMS5552 Alone in T2DM Subjects
A 24-week Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of HMS5552 With Additional 28-week Open-label Treatment to Evaluate the Safety of HMS5552 Alone in T2DM Subjects
Enrollment Status: Completed
Publish Date: August 26, 2021
Intervention Type: Drug
Study Drug: HMS5552
Study Phase: Phase 3
Phase III Study of Chiglitazar in Patients With Type 2 Diabetes Mellitus and Insufficient Glycemic Control Despite Diet and Exercise -- A Multicenter, Randomized, Double-Blind, and Sitagliptin-Controlled Trial
Phase III Study of Chiglitazar in Patients With Type 2 Diabetes Mellitus and Insufficient Glycemic Control Despite Diet and Exercise -- A Multicenter, Randomized, Double-Blind, and Sitagliptin-Controlled Trial
Enrollment Status: Completed
Publish Date: October 25, 2019
Intervention Type: Drug
Study Phase: Phase 3
The Cross-sectional and Longitudinal Study of Relationship Between Diabetes and Cognitive Impairment by Olfactory Function Assessment and Functional MRI in Obese and Normal Weight Diabetic Patients
The Cross-sectional and Longitudinal Study of Relationship Between Diabetes and Cognitive Impairment by Olfactory Function Assessment and Functional MRI in Obese and Normal Weight Diabetic Patients
Enrollment Status: Completed
Publish Date: May 30, 2019
Intervention Type: Other, Behavioral, Procedure
View 5 Less Clinical Trials

183 Total Publications

Application value of one-hour post-load glucose ≥8.6 mmol/L during oral glucose tolerance test in detecting prediabetes
Application value of one-hour post-load glucose ≥8.6 mmol/L during oral glucose tolerance test in detecting prediabetes
Journal: Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
Published: June 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Zhu's expertise for a condition
ConditionClose
    View All 38 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile